Gene Therapy

Area of Science:

• Biopharmaceuticals
• Biotechnology
• Genetics

Background:

• Gene therapy medicinal products (GTMPs) represent a promising frontier in biopharmaceuticals.
• Clinical research focuses on cancer and rare single-gene disorders, with advancements in ocular and hematopoietic applications.
• Marketed products include DNA-based therapies, antisense oligonucleotides, small interfering RNA, and T-cell therapies.

Purpose of the Study:

• To review the current state and future potential of gene therapy medicinal products.
• To highlight key applications in oncology and rare genetic diseases.
• To discuss challenges and opportunities in the gene therapy market.

Main Methods:

• Review of existing literature and marketed gene therapy products.
• Analysis of clinical research trends in cancer and rare diseases.
• Discussion of technological advancements, including CRISPR gene editing.

Main Results:

• GTMPs are demonstrating encouraging results in treating cancers resistant to conventional therapies.
• Significant progress has been made in developing GTMPs for rare single-gene disorders, particularly affecting the eye and hematopoietic system.
• CRISPR technology is poised to significantly impact the future development of gene therapy medicines.

Conclusions:

• Gene therapy offers substantial therapeutic potential but faces challenges in efficacy, safety, manufacturing, and cost.
• Addressing these challenges is crucial for ensuring patient access and the overall success of gene therapy.
• Continued innovation in gene delivery systems and manufacturing is essential for market growth.